NZ217645A - Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations - Google Patents

Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations

Info

Publication number
NZ217645A
NZ217645A NZ217645A NZ21764586A NZ217645A NZ 217645 A NZ217645 A NZ 217645A NZ 217645 A NZ217645 A NZ 217645A NZ 21764586 A NZ21764586 A NZ 21764586A NZ 217645 A NZ217645 A NZ 217645A
Authority
NZ
New Zealand
Prior art keywords
lav
htlv
recombinant viruses
vaccine formulations
viruses expressing
Prior art date
Application number
NZ217645A
Other languages
English (en)
Inventor
Hu Shiu-Lok
Anthony F Purchio
Linda Madisen
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen filed Critical Oncogen
Publication of NZ217645A publication Critical patent/NZ217645A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NZ217645A 1985-09-25 1986-09-22 Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations NZ217645A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77990985A 1985-09-25 1985-09-25
US84298486A 1986-03-27 1986-03-27
US90521786A 1986-09-09 1986-09-09

Publications (1)

Publication Number Publication Date
NZ217645A true NZ217645A (en) 1991-11-26

Family

ID=27419757

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ217645A NZ217645A (en) 1985-09-25 1986-09-22 Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations

Country Status (22)

Country Link
CN (1) CN1020752C (es)
AT (1) ATA256786A (es)
CH (1) CH676247A5 (es)
DE (1) DE3690508T1 (es)
DK (1) DK455486A (es)
ES (2) ES2002490A6 (es)
FI (1) FI863848A (es)
FR (1) FR2587720A2 (es)
GB (1) GB2181435B (es)
GR (1) GR862412B (es)
HU (1) HU205780B (es)
IE (1) IE59314B1 (es)
IL (1) IL80073A (es)
IT (1) IT1195829B (es)
MY (1) MY103182A (es)
NL (1) NL8602422A (es)
NO (1) NO863803L (es)
NZ (1) NZ217645A (es)
PT (1) PT83434B (es)
SE (4) SE8604007L (es)
WO (1) WO1987002038A1 (es)
YU (1) YU46753B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0220234B1 (en) * 1985-04-08 1994-08-03 Genetic Systems Corporation EXPRESSION AND DIAGNOSTIC USE OF gag ENCODED PEPTIDES WHICH ARE IMMUNOLOGICALLY REACTIVE WITH ANTIBODIES TO LAV
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
US4983387A (en) * 1986-05-19 1991-01-08 Viral Technologies Inc. HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
ATE107861T1 (de) * 1986-09-19 1994-07-15 Oncogen Verwendung von aktivierten t-lymphozyten zur vorbereitung einer pharmazeutischen zusammensetzung zur behandlung von aids.
IL84154A0 (en) * 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
EP0272858A3 (en) * 1986-12-15 1989-07-12 Repligen Corporation Recombinant hiv envelope proteins produced in insect cells
FR2610632B1 (fr) * 1987-02-11 1990-12-21 Pasteur Institut Peptides caracteristiques des retrovirus d'immunodeficience humaine (virus hiv) leurs applications au diagnostic des infections dues a certains de ces virus et, le cas echeant, a la vaccination contre le sida
WO1988005440A1 (fr) * 1987-01-16 1988-07-28 Institut Pasteur Peptides ayant des proprietes immunologiques 2-hiv-2
US5681713A (en) * 1987-05-08 1997-10-28 Smithkline Beecham Corporation Expression of heterologous proteins in Drosophila cells
GB8714802D0 (en) * 1987-06-24 1987-07-29 Proteus Biotech Ltd Synthetic polypeptides
DE10399032I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
FR2620030B1 (fr) * 1987-09-07 1990-03-23 Transgene Sa Vecteur d'expression des proteines du virus hiv-2, un agent causal du sida, culture cellulaire infectee ou transformee par ce vecteur, proteines obtenues, vaccin et anticorps obtenus
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
ATE110112T1 (de) * 1988-05-06 1994-09-15 Ferropas Ag Verfahren und systeme zur herstellung von hiv- antigenen.
US5043262A (en) * 1988-05-12 1991-08-27 Dana Farber Cancer Institute Protein, sequences containing the VPU gene therefore, vectors, methods of preparation and use
AP129A (en) * 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5614404A (en) * 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5631154A (en) * 1988-06-10 1997-05-20 Therion Biologics, Incorporated Self assembled, defective, non-self-propagating lentivirus particles
US5747324A (en) * 1988-06-10 1998-05-05 Therion Biologics Corporation Self-assembled, defective, non-self-propagating lentivirus particles
WO1989012095A1 (en) * 1988-06-10 1989-12-14 Applied Biotechnology, Inc. A method of evaluating recombinant vaccines against immunodeficiency virus
US5665577A (en) * 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
DE69031735T2 (de) * 1989-04-18 1998-03-12 Applied Biotechnology Inc Erzeugung von hybrid-genen und proteinen durch rekombination mittels viren
JP3034025B2 (ja) * 1989-06-01 2000-04-17 アプライド・バイオテクノロジー・インコーポレーテツド 自己アセンブルド欠損非自己増殖性ウイルス粒子
GB8923123D0 (en) 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
US5981276A (en) * 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5840312A (en) * 1991-05-02 1998-11-24 Institut Pasteur Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein
FR2676068B1 (fr) * 1991-05-02 1994-11-04 Pasteur Institut Souches recombinantes immunogenes de b. anthracis - compositions immunogenes les contenant.
ES2177530T3 (es) * 1991-11-08 2002-12-16 Upjohn Co Vacunas contra el virus de la leucemia felina.
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
WO1996024378A2 (en) * 1995-02-10 1996-08-15 Worcester Foundation For Biomedical Research, Inc. Delivery of exogenous compounds
US6013506A (en) * 1995-06-05 2000-01-11 Wardley; Richard C. Feline leukemia virus vaccines
ATE188783T1 (de) * 1995-09-06 2000-01-15 Schablonentechnik Kufstein Ag Verfahren zum herstellen einer siebdruckschablone
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US6723558B1 (en) 1996-01-23 2004-04-20 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US7368102B2 (en) 2001-12-19 2008-05-06 Nektar Therapeutics Pulmonary delivery of aminoglycosides

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3485810T2 (de) * 1983-05-27 1992-12-10 Texas A & M University Syst Verfahren zur herstellung eines rekombinanten baculovirus-expressionsvektors.
US4662514A (en) * 1983-11-01 1987-05-05 Charleswater Products, Inc. Electrically conductive polymeric tubes for static sensitive electronic devices
US9328391B1 (en) * 1984-08-22 2016-05-03 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cloning and expression of HIV-1 DNA
IL76082A (en) * 1984-08-22 1991-07-18 Us Health Molecular clones of the genome of htlv-iii and a process for the preparation thereof
GB8501473D0 (en) * 1985-01-21 1985-02-20 Pasteur Institut Cloned dna sequences
KR930000189B1 (ko) * 1984-10-18 1993-01-11 앵스뛰띠 빠스뙤르 임파선증과 후천성 면역 결핍증 바이러스의 항원을 제조하는 방법 및 이 항원에 대한 항체의 생산 방법
CA1341482C (en) * 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
ATE138100T1 (de) * 1984-12-24 1996-06-15 Genentech Inc Fusionen von aids-verwandten polypeptiden
US4774175A (en) * 1985-03-01 1988-09-27 Centocor, Inc. Immunochemical methods for the detection of antibody against HTLV-III
NZ215867A (en) * 1985-04-19 1989-10-27 Hoffmann La Roche Aids envelope protein, dna vectors and method of production
FR2586427B1 (fr) * 1985-08-20 1988-12-09 Pasteur Institut Sequences de nucleotides et de polypeptides issus du virus visna et leur application a des essais de diagnostic et a la production de compositions immunogenes

Also Published As

Publication number Publication date
ATA256786A (de) 1995-05-15
SE9102976L (sv) 1993-04-15
NL8602422A (nl) 1987-04-16
GB2181435A (en) 1987-04-23
SE8604007L (sv) 1987-03-26
CH676247A5 (es) 1990-12-28
FI863848A0 (fi) 1986-09-24
MY103182A (en) 1993-05-29
IT1195829B (it) 1988-10-27
YU46753B (sh) 1994-05-10
FR2587720A2 (fr) 1987-03-27
WO1987002038A1 (en) 1987-04-09
ES2002490A6 (es) 1988-08-16
IL80073A (en) 1995-01-24
DE3690508T1 (es) 1988-06-23
HUT42133A (en) 1987-06-29
SE9102974L (sv) 1993-04-15
FR2587720B2 (es) 1995-02-10
IE59314B1 (en) 1994-02-09
CN86106632A (zh) 1987-05-13
GB2181435B (en) 1990-01-10
PT83434B (pt) 1988-07-29
IT8667730A0 (it) 1986-09-24
SE8604007D0 (sv) 1986-09-23
NO863803D0 (no) 1986-09-24
YU165486A (en) 1989-08-31
SE9102975D0 (sv) 1991-10-14
DK455486A (da) 1987-03-26
NO863803L (no) 1987-03-26
CN1020752C (zh) 1993-05-19
FI863848A (fi) 1987-03-26
DK455486D0 (da) 1986-09-24
IE862525L (en) 1987-03-25
SE9102974D0 (sv) 1991-10-14
SE9102976D0 (sv) 1991-10-14
IL80073A0 (en) 1986-12-31
HU205780B (en) 1992-06-29
ES2006941A6 (es) 1989-05-16
PT83434A (en) 1986-10-01
SE9102975L (sv) 1993-04-15
GR862412B (en) 1987-01-23
GB8622987D0 (en) 1986-10-29

Similar Documents

Publication Publication Date Title
NZ217645A (en) Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations
JPS6425800A (en) T-cell epitope of hepatities b virus nucleocapside protein
DK437883A (da) Vandige mikroemulsioner, deres fremstilling og anvendelse
GB8907914D0 (en) Vaccine preparation
DK664187D0 (da) Hydrosolpraeparater
HU906229D0 (en) Medical preparations
DE3890874C5 (de) Rekombinante Viren
EP0256878A3 (en) Vaccines
DK551187D0 (da) Terapeutisk praeparat og dettes fremstilling
NZ224046A (en) Hiv antigenic peptide fragments and their use
DK412787D0 (da) Medicinsk-kirurgisk pose og dennes fremstilling
JPS54147692A (en) Dental bridge and its preparation
GB2203740B (en) Novel peptides, their preparation and use
IL83347A0 (en) Recombinant htlv-iii proteins and their use
DK259184D0 (da) Immunogene praeparater
IL81568A0 (en) Plasmids which inhibit human t-cell lymphotropic virus type iii replication
DK575787A (da) Rekombinant hcmv-afledt plasmid, dets fremstilling og anvendelse
DK698188A (da) Peptider, deres fremstilling og anvendelse
GB8615995D0 (en) Veterinary preparations
IL79740A0 (en) Hepatitis vaccine
IL81920A0 (en) Vaccines and their preparation
ZA876168B (en) Human low fc epsilon-receptor,the isolation,the recombinant preparation and purification thereof
PH23582A (en) Veterinary preparations
GB2142334B (en) Immunogenic preparations
NZ233255A (en) Plasmodium cs protein analogues lacking one or more of the repeat epitopes, and containing at least one nonrepeat flanking epitope